Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Avalo Therapeutics, Inc. (NASDAQ:AVTX) was the recipient of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 76,000 shares, an increase of 75.5% from the January 31st total of 43,300 shares. Currently, 0.9% of the shares of the company are short sold. Based on an average daily volume of 88,800 shares, the days-to-cover ratio is currently 0.9 days.

Hedge Funds Weigh In On Avalo Therapeutics

A number of large investors have recently modified their holdings of AVTX. Tower Research Capital LLC TRC raised its stake in shares of Avalo Therapeutics by 998.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after buying an additional 3,754 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $114,000. Walleye Capital LLC purchased a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $145,000. Northern Trust Corp purchased a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $168,000. Finally, Bank of Montreal Can purchased a new position in shares of Avalo Therapeutics during the 4th quarter worth approximately $446,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AVTX has been the subject of a number of research analyst reports. Wedbush initiated coverage on Avalo Therapeutics in a research report on Friday, February 21st. They issued an “outperform” rating and a $18.00 target price for the company. Piper Sandler began coverage on Avalo Therapeutics in a research report on Friday. They issued an “overweight” rating and a $48.00 target price for the company. Finally, BTIG Research began coverage on Avalo Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective for the company. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Avalo Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $35.33.

Avalo Therapeutics Stock Down 8.3 %

Avalo Therapeutics stock opened at $6.70 on Tuesday. Avalo Therapeutics has a twelve month low of $4.35 and a twelve month high of $34.46. The stock has a 50 day moving average of $7.55 and a two-hundred day moving average of $9.25.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.